Non-small Cell Lung Cancer

Segment 8 - Treatment's Financial Constraints
January 02, 2014 – 
The panelists discuss clinicians and their perspectives on financial constraints in treatment of NSCLC.
Segment 7 - Cost Considerations
January 02, 2014 – 
Dr Peskin begins by stating, costs are exceedingly consequential. Cancer care and treatment is occupying, and with demographics being what they are, increasingly larger relative total cost of care across the US, including various national organizations.
Segment 6 - Molecular Testing
January 02, 2014 – 
Panelists continue to discuss the use of screening, including PET scanning. They then transition into discussions about molecular testing.
Segment 5 - Value-based Decisions in NSCLC
January 02, 2014 – 
Dr Peskin discusses programs such as Choosing Wisely and how providers must be mindful of high value, cost-conscious, cost-aware care.
Segment 4 - Screening
December 30, 2013 – 
Panelists discuss screening recommendations and guidelines, including considerations for screening those patients with a smoking history.
Segment 3 - Treatment Considerations
December 30, 2013 – 
The panelists weigh in on the appropriate standards for treating patients with NSCLC.
Segment 2 - Histology, Targeted Therapy and Surgery
December 30, 2013 – 
Dr Langer suggests that historically, there's been a monolithic approach to treating NSCLC.
Segment 1 - Introduction to NSCLC
December 30, 2013 – 
Moderator Michael Chernew, MD, introduces panelists as they discuss the treatment overview of non-small cell lung cancer (NSCLC).
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.